Diagnostic, prognostic, and predictive biomarkers in pancreatic cancer

Winter, Jordan M.; Yeo, Charles J.; Brody, Jonathan R.

doi:10.1002/jso.23192

Cited by 204 publications

(166 citation statements)

References 81 publications

Supporting

Mentioning

156

Contrasting

Unclassified

Order By: Relevance

“…The use of CEA as a biomarker for pancreatic adenocarcinoma was investigated, but compared to CA 19-9, it was found to be less sensitive and specific for pancreatic cancer (Winter et al, 2013). A study by Ishii et al (1996) showed that performance status, CEA levels <10 ng/mL, and absence of distant metastases before treatment were statistically significant prognostic factors that affected survival.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Evaluation of Prognostic Factors and Survival Results in Pancreatic Carcinomas in Turkey

Canyılmaz

Serdar²,

Uslu³

et al. 2013

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: The goal of this retrospective study was to evaluate patient characteristics, treatment modalities and prognostic factors in Turkish patients with pancreatic cancer. Materials and Methods: Between January 1997 and December 2012, 64 patients who presented to the Department of Radiation Oncology, Karadeniz Technical University, Faculty of Medicine with a diagnosis of pancreatic cancer were evaluated. The E/K ratio of the cases was 2.4/1 and the median age was 59.6 (32-80) years, respectively. Some 11 cases (18%) were stage 1, 21 (34.4%) were stage 2, 10 (16.4%) were stage 3, and 19 (31.1%) were metastatic. Results: The mean follow-up time was 15.7 months (0.7-117.5) and loco-regional recurrence was noted in 11 (40.7%) who underwent surgery while metastases were observed in 41 patients (66.1%). The median overall survival (OS) was 11.2 months and the 1, 3 and 5-year OS rates were 41.7%, 9.9% and 7.9% respectively. The median disease-free survival (DFS) was 5.2 month and the1, 2 and 5 year DFS were 22.6%, 7.6% and 3.8% respectively. On univariate analysis, prognostic factors affecting OS included status of the operation (p<0.001), tumor stage (p=0.008), ECOG performance status (p=0.005) and CEA level (p=0.017).On multivariate analysis, prognostic factors affecting survival included status of the operation (p=0.033) and age (p= 0.023). Conclusions: In the current study, age and operation status were independent prognostic factors for overall survival with pancreatic patients. Thus, the patients early diagnosis and treatment ars essential. However, prospective studies with more patients are needed for confirmation.

show abstract

Section: Discussionmentioning

confidence: 99%

“…It is used to determine prognosis and tumor burden (recurrence or progression) (Winter et al, 2013). In many studies, the CA 19-9 level was included among well-known prognostic factors (Boeck et al, 2007;Bernhard et al, 2010).…”

Section: Discussionmentioning

confidence: 99%

Evaluation of Prognostic Factors and Survival Results in Pancreatic Carcinomas in Turkey

Canyılmaz

Serdar²,

Uslu³

et al. 2013

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…Late diagnosis of PDAC and the limited response to current treatments result in an exceptionally poor prognosis (Ferrone et al, 2012). At present, prognostic biomarkers of PDAC are relatively lacked which also results in a relatively unavailable monitoring of the progressing (Winter et al, 2012). Therefore, an efficient prognostic marker has an extreme urgency.…”

Section: Introductionmentioning

confidence: 99%

Prognostic Significance of Annexin A1 Expression in Pancreatic Ductal Adenocarcinoma

Chen¹,

Shen²,

Wang³

et al. 2012

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Annexin A1 is a 37-kDa calcium-and phospholipid-binding protein of the annexin superfamily considered to play an important role in tumorigenesis. However, associations with clinicopathological features in pancreatic ductal adenocarcinoma (PDAC) cases have yet to be fully defined. We therefore investigated the prognostic value of annexin A1 protein as a PDAC biomarker in 83 tumor and matched non-cancerous tissues or normal pancreas tissues. Expression was analyzed using real-time RT-PCR, Western blotting and immunohistochemistry. In non-tumor tissue, myoepithelial cells showed no or weak expression of annexin A1 while expression was strong and sometimes even located in the nuclei of endothelial cells in tumor tissue. High expression was significantly associated with advanced stage (P <0.05) and a worse overall survival (P <0.05). These results provide new insights to better understand the role of annexin A1 in PDAC survival, and might be relevant to prediction of prognosis and development of more effective therapeutic strategies aimed at improving survival.

show abstract

“…Accurate prediction of the prognosis of each individual pancreatic cancer patient is of great importance, and molecular biomarkers functioning as prognostic factors could be useful in determining an individualized treatment plan for each pancreatic cancer patient (Hurwitz et al, 1992). However, the biomarkers that are currently in use are not satisfactory; therefore, there is a need for the identification and development of additional markers to fine-tune this process (Winter et al, 2013). miRNA, which function as key post-transcription regulators, are involved in a wide variety of biological processes, including cell growth, development, proliferation, differentiation, and death (Esquela- Kerscher and Slack, 2006).…”

Section: Discussionmentioning

confidence: 99%

Reduced miRNA-218 expression in pancreatic cancer patients as a predictor of poor prognosis

2015

Genet. Mol. Res.

View full text Add to dashboard Cite

ABSTRACT. microRNA-218 (miR-218) is a vertebrate-specific miRNA that plays a crucial role in tumorigenesis and tumor progression. This study analyzed the miR-218 expression level and clinical significance in pancreatic cancer. One hundred and seven pairs of pancreatic cancer and adjacent normal tissues were analyzed by quantitative reversetranscriptase polymerase chain reaction. The correlation between miR-218 expression and clinicopathological characters was determined by the two-sample Student t-test. The survival correlations were analyzed by the Kaplan-Meier method and Cox proportional hazards model. The relative expression of miR-218 in pancreatic cancer tissues (2.63 ± 1.59) was significantly lower than that in matched noncancerous pancreatic tissues (6.52 ± 2.50, P < 0.001). The low expression of miR-218 in the pancreatic cancer tissues were strongly correlated with the TNM classification (P = 0.02), distant metastasis (P = 0.001), and tumor differentiation (P = 0.003). The low level of miR-218 expression was significantly correlated with the shorter overall survival time of pancreatic cancer patients (5-year overall survival rate: 7.5 vs 34.9%; log-rank test: P < 0.001). Multivariate analyses confirmed that a low level of miR-218 expression was an independent 16373 miR-218 is a prognosis factor for pancreatic cancer ©FUNPEC-RP www.funpecrp.com.br Genetics and Molecular Research 14 (4): 16372-16378 (2015) predictor of poor prognosis in pancreatic cancer patients (Hazard ratio: 7.24; 95% confidence interval: 2.01-18.28; P = 0.007). Our findings suggested a significant downregulation in the expression of miR-218; this might have considerable potential value in the prognosis for pancreatic cancer.

show abstract

Diagnostic, prognostic, and predictive biomarkers in pancreatic cancer

Cited by 204 publications

References 81 publications

Evaluation of Prognostic Factors and Survival Results in Pancreatic Carcinomas in Turkey

Evaluation of Prognostic Factors and Survival Results in Pancreatic Carcinomas in Turkey

Prognostic Significance of Annexin A1 Expression in Pancreatic Ductal Adenocarcinoma

Reduced miRNA-218 expression in pancreatic cancer patients as a predictor of poor prognosis

Contact Info

Product

Resources

About